In Reply Dr Siegel and colleagues at the FDA raise concerns that our article incorrectly indicated that the FDA relies only on meta-analyses to establish surrogacy and “incorrectly identifies the evidence the FDA used to conclude that these biomarkers can serve as surrogate end points.” However, nowhere in the article did we state that the FDA relies only on meta-analyses to establish the surrogacy of a biomarker for a clinical outcome.
